Takeda Hits Accelerator On TAK-861 After Phase II Narcolepsy Win
The drug maker plans to move the drug into Phase III development for NT1, though it appears to have missed on NT2. But a lack of key toxicities may bode well for the orexin agonist class too.
You may also be interested in...
After Alkermes spun out its oncology assets into a separate public entity so the company could focus exclusively on neuroscience, CEO Richard Pops said it will look externally to build its pipeline.
Fiscal Q2 figures in line with expectations but investors digest surprise trial halt and share buyback.
The company stopped Phase II clinical trials for TAK-994 to assess a safety signal and determine next steps for the drug, which is viewed as a key product in Takeda’s push for blockbuster revenue growth.